ELSEVIER

Contents lists available at ScienceDirect

Journal of Virological Methods

journal homepage: www.elsevier.com/locate/jviromet



A generic assay for whole-genome amplification and deep sequencing of enterovirus A71



Le Van Tan ^{a,*}, Nguyen Thi Kim Tuyen ^a, Tran Tan Thanh ^a, Tran Thuy Ngan ^a, Hoang Minh Tu Van ^{a,b}, Saraswathy Sabanathan ^{a,c}, Tran Thi My Van ^d, Le Thi My Thanh ^d, Lam Anh Nguyet ^a, Jemma L. Geoghegan ^e, Kien Chai Ong ^f, David Perera ^g, Vu Thi Ty Hang ^a, Nguyen Thi Han Ny ^a, Nguyen To Anh ^a, Do Quang Ha ^a, Phan Tu Qui ^{a,d}, Do Chau Viet ^b, Ha Manh Tuan ^b, Kum Thong Wong ^f, Edward C. Holmes ^e, Nguyen Van Vinh Chau ^d, Guy Thwaites ^{a,c}, H. Rogier van Doorn ^{a,c}

- ^a Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam
- ^b Children's Hospital 2, Ho Chi Minh City, Viet Nam
- ^c Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- ^d Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam
- e Mahir Bashir Institute for Infectious Diseases & Biosecurity, Charles Perkins Centre, School of Biological Science and Sydney Medical School, The University of Sydney, Sydney, Australia
- ^f University of Malaya, Kuala Lumpur, Malaysia
- g Institute of Health and Community Medicine, Universiti Malaysia Sarawak, Sarawak, Malaysia

Article history: Received 22 October 2014 Received in revised form 24 January 2015 Accepted 11 February 2015 Available online 19 February 2015

Keywords: Enterovirus A71 Picornavirus Hand foot and mouth disease Deep sequencing Phylogeny

ABSTRACT

Enterovirus A71 (EV-A71) has emerged as the most important cause of large outbreaks of severe and sometimes fatal hand, foot and mouth disease (HFMD) across the Asia-Pacific region. EV-A71 outbreaks have been associated with (sub)genogroup switches, sometimes accompanied by recombination events. Understanding EV-A71 population dynamics is therefore essential for understanding this emerging infection, and may provide pivotal information for vaccine development. Despite the public health burden of EV-A71, relatively few EV-A71 complete-genome sequences are available for analysis and from limited geographical localities. The availability of an efficient procedure for whole-genome sequencing would stimulate effort to generate more viral sequence data. Herein, we report for the first time the development of a next-generation sequencing based protocol for whole-genome sequencing of EV-A71 directly from clinical specimens. We were able to sequence viruses of subgenogroup C4 and B5, while RNA from culture materials of diverse EV-A71 subgenogroups belonging to both genogroup B and C was successfully amplified. The nature of intra-host genetic diversity was explored in 22 clinical samples, revealing 107 positions carrying minor variants (ranging from 0 to 15 variants per sample). Our analysis of EV-A71 strains sampled in 2013 showed that they all belonged to subgenogroup B5, representing the first report of this subgenogroup in Vietnam. In conclusion, we have successfully developed a high-throughput next-generation sequencing-based assay for whole-genome sequencing of EV-A71 from clinical samples. © 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Enterovirus A71 (EV-A71) belongs to the Enterovirus A species of the family *Picornaviridae*, and is genetically divided into three genogroups (A, B, and C). The latter two are further divided into

subgenogroups, denoted B0 – 5 and C1 – 5, respectively. Since 1997, EV-A71 has emerged as the most important cause of large outbreaks of severe and sometimes fatal hand, foot and mouth disease (HFMD) across the Asia-Pacific region (Solomon et al., 2010; Xing et al., 2014). In Vietnam, EV-A71-related HFMD was first described in 2003, and became a notifiable illness in 2008. Between 2011 and 2012, more than 200,000 hospitalized cases due to HFMD were reported in Vietnam, of which 207 died as a consequence of clinical complications (including cardio-pulmonary compromise with

^{*} Corresponding author. Tel.: +84 8 8384009; fax: +84 8 9238904. E-mail address: tanly@oucru.org (L.V. Tan).